Sartorius AG (SDMHF.PK), an international laboratory and pharmaceutical equipment supplier, reported that its first quarter of 2015 preliminary Group sales growth was around 17% in constant currencies, reaching about 258 million euros in consolidated revenue.
The growth was driven primarily by the Bioprocess Solutions Division. Due to the low prior-year revenue base, the company had expected above-average growth rates for this first quarter. Nevertheless, the gains supported by strong performance in all product segments were higher than projected at the beginning of the year.
Sartorius noted that it has revised its forecast upwards for the full year of 2015. Sales revenue in constant currencies is now expected to increase by approximately 6% to 9%, compared to previous guidance of about 4% to 7%. It projects that the company's underlying EBITDA margin in constant currencies will increase to around 22%, compared to previous guidance of around 21.5%.
The company said that further information will be published as part of the company's first-quarter reporting activities on April 20, 2015.
For comments and feedback: editorial@rttnews.com